Harvest Fund Management Co. Ltd Has $582,000 Holdings in Novo Nordisk A/S (NYSE:NVO)

Harvest Fund Management Co. Ltd boosted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 124.5% in the fourth quarter, Holdings Channel.com reports. The firm owned 5,626 shares of the company’s stock after acquiring an additional 3,120 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Novo Nordisk A/S were worth $582,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the company. Clarius Group LLC grew its holdings in Novo Nordisk A/S by 0.5% during the fourth quarter. Clarius Group LLC now owns 18,505 shares of the company’s stock worth $1,914,000 after purchasing an additional 93 shares during the period. Tradewinds Capital Management LLC lifted its stake in Novo Nordisk A/S by 2.0% during the fourth quarter. Tradewinds Capital Management LLC now owns 4,955 shares of the company’s stock worth $513,000 after purchasing an additional 95 shares during the last quarter. Relyea Zuckerberg Hanson LLC increased its holdings in shares of Novo Nordisk A/S by 3.2% during the fourth quarter. Relyea Zuckerberg Hanson LLC now owns 3,159 shares of the company’s stock worth $327,000 after buying an additional 99 shares in the last quarter. Fort Washington Investment Advisors Inc. OH increased its holdings in shares of Novo Nordisk A/S by 3.5% during the fourth quarter. Fort Washington Investment Advisors Inc. OH now owns 2,960 shares of the company’s stock worth $306,000 after buying an additional 100 shares in the last quarter. Finally, Highlander Capital Management LLC increased its holdings in shares of Novo Nordisk A/S by 0.4% during the fourth quarter. Highlander Capital Management LLC now owns 25,100 shares of the company’s stock worth $2,597,000 after buying an additional 100 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on NVO shares. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Tuesday, January 23rd. They issued an “overweight” rating and a $120.00 price objective for the company. BMO Capital Markets began coverage on shares of Novo Nordisk A/S in a research report on Friday, April 12th. They issued an “outperform” rating and a $163.00 price target on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $160.00 price objective on shares of Novo Nordisk A/S in a research note on Thursday, April 18th. Finally, UBS Group assumed coverage on shares of Novo Nordisk A/S in a research note on Tuesday, January 16th. They issued a “neutral” rating for the company. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Moderate Buy” and a consensus price target of $133.60.

Novo Nordisk A/S Stock Performance

NVO stock traded down $2.48 during midday trading on Wednesday, reaching $126.16. The stock had a trading volume of 3,092,421 shares, compared to its average volume of 4,833,965. The firm has a fifty day simple moving average of $126.66 and a two-hundred day simple moving average of $111.54. The stock has a market cap of $566.15 billion, a PE ratio of 46.42, a P/E/G ratio of 2.09 and a beta of 0.41. Novo Nordisk A/S has a 52-week low of $75.56 and a 52-week high of $138.28. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.64 and a current ratio of 0.82.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, January 31st. The company reported $0.71 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.05. The business had revenue of $9.51 billion for the quarter, compared to analysts’ expectations of $9.14 billion. Novo Nordisk A/S had a return on equity of 90.36% and a net margin of 36.03%. As a group, equities research analysts anticipate that Novo Nordisk A/S will post 3.32 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently disclosed a Semi-Annual dividend, which was paid on Tuesday, April 2nd. Stockholders of record on Monday, March 25th were paid a $0.664 dividend. This is a boost from Novo Nordisk A/S’s previous Semi-Annual dividend of $0.22. This represents a dividend yield of 0.9%. The ex-dividend date of this dividend was Friday, March 22nd. Novo Nordisk A/S’s dividend payout ratio (DPR) is presently 49.17%.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.